

Oxazepine Derivative as an Antitumor Agent and Snail1 Inhibitor against Human Colorectal Adenocarcinoma

Dhanya Sunil¹, Ranjitha C¹, Rama M¹, KSR Pai²

Assistant Professor, Department of Chemistry, Manipal Institute of Technology, Manipal University, Karnataka, India¹

Professor, Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal University, Karnataka,
India²

ABSTRACT: Colorectal cancer is the third most common malignancy in man, with significant morbidity and mortality. Metastasis, the major cause of cancer-associated deaths occurs as a multistep process, where cancer cells detach from the primary tumor, intravasate circulation to disseminate and invade surrounding tissues to form the secondary tumors. The effectiveness of many anticancer drugs is limited by their toxicity to normal rapidly growing cells. Four oxazepines were synthesized by the cycloaddition reaction between schiff bases and maleic anhydride, which were characterized by CHN analysis and advanced spectral techniques. The cytotoxicity of oxazepines against HCT116 (human colon cancer) cell lines were studied using Sulphorhodamine-B (SRB) assay, and their antimigratory properties using wound healing assay. 1-[2-(2,3-dihydro-1*H*-indol-3-yl)-4,7-dioxo-4,7-dihydro-1,3-oxazepin-3(2*H*)-yl]thiourea (2b) exhibited very low IC₅₀ in SRB assay with good antimigratory activity as observed in wound healing assay. Snail 1, a transcription regulator of E-cadherin induces epithelial-to mesenchymal transition, reduces intercellular adhesion and increases cell motility, endows epithelial cancer cells with migration and invasive properties. Snail1 is upregulated in several human cancers and is frequently associated with apoptotic resistance, invasiveness, metastases and poor prognosis and it can act as a molecular target in cancer treatment. The docking studies of 2b with the active site of snail1 suggest it to be a potent chemotherapeutic agent in the treatment of colorectal cancer.

KEYWORDS: Oxazepines, Anticancer, Migration, HCT116, Snail1.

I. INTRODUCTION

Human colon cancer is one of the most commonly diagnosed cancers mainly occurring due to lifestyle and increasing age accounting for 30 % of all cancer deaths. The primary treatment involves surgery followed by chemotherapy. Unfortunately, synthesized anticancer drugs fail to distinguish between malignant cells and normal cells and target the metabolically active cells with an added disadvantage of unpleasant side effects. The development of novel approaches in diagnostic methods and synthesis of new selective anticancer drugs having high efficiency, low toxicity, and minimum side effects by developing new approaches based on the advances in knowledge of cancer biology is the major requirement of the current drug research and development in cancer therapy.

Oxazepine is unsaturated non-homologous seven membered heterocycle containing oxygen in position 1 and nitrogen in position 3 in addition to the five carbon atoms. It is prepared by the pericycliccycloaddition of schiff bases with maleic, phthalic, nitrophthalic and succinic anhydrides [1]. Oxazepine derivatives was found to exhibit a vast variety of biological activities like antibacterial [2], antifungal [3], hypnotic muscle relaxant [4], antagonistic [5], anti-inflammatory [6], telomerase inhibitors [7] and antiepileptic [8]. Dibenzob[*b,f*][1,4]oxazepine has been taken up to the design of potent progesterone receptor antagonists, p38 MAP kinase inhibitors, TRPAI ion channel modulators and histone deacetylase inhibitors [9]. Aryl-annulated[1,4]oxazepine is found to be a vital moiety in many psychoactive pharmaceuticals.

International Journal of Innovative Research in Science, Engineering and Technology

(An ISO 3297: 2007 Certified Organization)


Vol. 3, Issue 8, August 2014

Snail1 is a repressor of the invasion suppressor gene CDH1, thereby leading to the transcriptional suppression of crucial transmembrane adhesion glycoprotein E-cadherin [10,11]. The loss of E-cadherin expression leads to a phenotypic change in cells, reducing cell-cell contacts as observed in Epithelial-mesenchymal transition (EMT), giving way to invasion, motility, increased apoptotic resistance and tumor proliferation [12]. EMT, which is pivotal in embryonic development for the correct implantation of the embryo and organogenesis, is normally inactive in differentiated somatic cells [13,14]. Downregulation of E-cadherin reactivates EMT; thereby cancer cells gain the ability to invade and metastasize, which is an important event in tumor progression [15]. Snail 1 has recently been shown to revoke the inhibition of the Wnt/beta-Catenin pathway caused by the anti-tumoral compound 1 α ,25-dihydroxyvitamin D3 [16,17]. Snail 1 is upregulated and frequently associated with invasiveness, metastases and poor prognosis in several human cancers [18-22]. Snail 1 is upregulated (in tumor-stroma interphase) in 60-70 % of colorectal adenoma and colorectal cancers [23]. In a recently published study of stage II colorectal cancer tissues, tumor buds was associated with increased levels of Snail 1 expression as well as a high incidence of metachronous lymph node metastasis [24,25]. The present study encompasses the synthesis, antitumor and antimigratory studies of oxazepines and their docking studies with Snail 1.

II. MATERIALS AND METHODS

A. Chemistry

Four Schiff bases were prepared by the amino condensation of thiosemicarbazones and aromatic aldehydes. Oxazepines were synthesized by the cycloaddition of schiff bases with maleic anhydride as depicted in scheme-1.



Scheme. 1. Synthetic route for (2E)-2-(substituted)hydrazinecarbothioamide (**1a-d**) and 3-[(Z)-(4-substitutedphenyl)methylidene]amino}-2-thioxoimidazolidin-4-one (**2a-d**)

Thin layer chromatography was performed on 0.25 mm silica gel plates using a 3:7 mixture of ethyl acetate and hexane as eluent and identified in UV chamber to monitor the progress of reaction and to check the purity of oxazepines. Melting points were determined by open capillary method and were uncorrected. The elemental analysis of the newly synthesized compounds was carried out in Flash thermo 1112 series CHN analyser.

B. Anticancer activity

All the compounds synthesized were studied for their anticancer properties in HCT116 (colon-carcinoma) cells cultured in Dulbecco's Modified Eagles Medium (DMEM) with 10 % Fetal Bovine Serum (FBS) in 5 % CO₂ atmosphere at 37 °C.

Sulphorhodamine-B (SRB) assay: HCT116 cells were seeded at a density of 10⁴ cells/well in 100 μ L of medium in 96-well plates and incubated for 24 hours at 37 °C in CO₂ atmosphere. Oxazepines were dissolved in 0.2 % DMSO and diluted with media. The cells were then treated with different concentrations (12.5-200 μ g/mL; 100 μ L/well) of oxazepines. Medium containing 0.2 % DMSO was added to control wells. After 48 h incubation, 50 μ L of ice cold 30

International Journal of Innovative Research in Science, Engineering and Technology

(An ISO 3297: 2007 Certified Organization)

Vol. 3, Issue 8, August 2014

% TCA was added to each well, incubated at 4 °C for 1 h and washed with distilled water. Further, 50 µL of 0.05 % w/v (in 1% acetic acid) SRB solution was added, incubated in dark for 30 min, plate rinsed with 1 % acetic acid and dried at room temperature. Finally, 10 mM Tris base was added and the absorbance was read at 540 nm on a scanning multi-well plate reader (ELx800, BioTek Instruments Inc., Winooski, VT, USA). The percentage of cell death for SRB assay was calculated using the following formula:

$$\% \text{ cytotoxicity} = [(C_A - B_A) - (T_A - B_A)] / (C_A - B_A)$$

Where, C_A , T_A and B_A are absorbance of control, test (oxazepines) and blank, respectively [26].

Monolayer wound healing assay: Cell migration or motility of HCT116 which is crucial to tissue repair, as well as cancer invasion and metastasis was studied using wound healing assay [27]. A wound gap in a cell monolayer is created by scratch, followed by monitoring the “healing” of this gap by cell migrating and growth towards the center of the gap, hereby filling up the “gap”. Cells were seeded in 6-well plates at a density of 1×10^5 cells/well containing DMEM media supplemented with 10 % FBS and incubated till cell growth of 80 % confluence was achieved. The media was aspirated and a single scrape (wound) was created in a linear fashion throughout the center of the plate using a sterile 1 mL micropipette tip to create a denuded zone. Then, cellular debris was removed by washing with phosphate buffer saline (PBS) and the cells were exposed to doxorubicin (1 µg/mL) and 2b (10 µg/mL) in DMEM media. The distance of cell migration (wound closure in µm) were measured using microscope stage micrometer and eye piece micrometer at 45× objective in each well at 24 h and 48 h. The digital images were captured using a CCD camera attached to inverted microscope (Nikon Eclipse TS100) soon after creating the wound and at 24 and 48 h after drug treatment. Analyses were performed in triplicates. The migration distance was calculated by subtracting the width of the injury line (at 24 h or 48 h) from the initial width of the injury line (at 0 h) and expressed in µm.

$$\frac{A - (B \text{ or } C \text{ or } D) \times 100}{A}$$

A

Where A = initial width of the injury line at 0 h; B = width of the injury line in the control; C = width of the injury line at 24 h; D = width of the injury line at 48 h.

C. Molecular modeling and docking studies

Human Snail 1 crystal structure complexed with FAD with a resolution of 3 Å and corresponding entry code 2Y48 was recovered from the PDB database (www.pdb.org). Surflex dock module of sybylver 1.7 was used (Tripos Inc. St. Louis, USA) and protocol was generated based on already complexed ligand residues (i.e. FAD) for carrying out docking studies. The proprietary software is licensed to Manipal Institute of Technology, Manipal University, India. The ligands were built using ligand preparation module of surflex descriptors. The best favorable conformation in terms of highest docking score was chosen. The agreement of DMPM to Lipinski's rule of five was evaluated [28].

III. RESULTS AND DISCUSSION

FT-IR spectra of oxazepines were recorded in KBr pellet using Shimadzu-8400S spectrometer. The formation of oxazepines were confirmed by the disappearance of a strong absorption due to C=N of schiff bases and $1800\text{-}1955\text{ cm}^{-1}$ for pure maleic anhydride and the presence of a new strong absorption at $1720\text{-}1650\text{ cm}^{-1}$ due to C=O str. The $^1\text{H-NMR}$ spectrum of oxazepines in DMSO- d_6 solvent and TMS as internal standard recorded in Bruker spectrometer showed the aromatic protons around δ 7.4-6.3 ppm and NH and NH₂ protons at 9.8 ppm and 2.5 respectively. The mass spectra of oxazepines recorded in a Shimadzu GCMS-QP5050 showed molecular ion peaks which were in accordance with their respective molecular masses.

Oxazepine **2b** with an indole substituent was found to be the most potent among all four oxazepines against HCT116 with a very low IC₅₀ of $13.2 \pm 0.1\text{ }\mu\text{g/mL}$ after 48 h incubation. **2a** with 4-hydroxyphenyl substituent displayed an IC₅₀ of $32.1 \pm 1.7\text{ }\mu\text{g/mL}$. **2c** and **2d** exhibited relatively less potency with IC₅₀ 50.4 ± 4.0 and $84.8 \pm 2.7\text{ }\mu\text{g/mL}$ respectively. All values are expressed as mean \pm SEM (n = 3). Compound **2b** which displayed minimum IC₅₀ value was selected to

International Journal of Innovative Research in Science, Engineering and Technology

(An ISO 3297: 2007 Certified Organization)

Vol. 3, Issue 8, August 2014

determine the motility of HCT116 cells in *in vitro* scratch wound healing assay. Fig 1. displays the wound gap after 24 h and 48 h of wound generation for control, standard Doxorubicin (1 µg/mL) and **2b** (10 µg/mL).




Fig.1.Graph depicting the wound gap in control, standard and 2b. At 24 h, the cell migration in 2b treated plate was comparable to that treated with Dox.

Fig 2 shows cell migration across a wound inflicted in an HCT116 cell monolayer for the control, standard doxorubicin (1 µg/mL) and **2b** (10 µg/mL). At the end of 24 h, the wound gap in cells treated with **2b** was almost same as that in the case of standard, showing the efficacy of **2b** in restricting cell migration. Fig 2 clearly indicates that after 48 h following application of the wound, the HCT116 cells were less motile and could not close the wound gap ($p < 0.05$), whereas in the control, the cells could completely heal the wound.




Fig. 2.The effect of **2b** on HCT116 migration. **2b** prevents the migration of cells, when compared to the respective control and Doxorubicin

EMT plays important physiological role during wound healing and is also crucial for the acquisition of tumoral invasiveness, the initial step of metastatic cascade in cancer [29].The best docking pose where **2b** lies deep into the Snail 1 binding cavity representing the ligand-protein interaction and the binding mode is depicted in Fig.3. **2b** have hydrogen bonded interaction with the surrounding cage of amino acids within the binding pocket of Snail 1 (Fig. 4).




Fig.3: Docked conformer of **2b** (coloured red)

Fig.4: Interaction of **2b** with active site residues in Snail 1

Docking of **2b** resulted in high scoring orientations and favourable docking score of 4.06 presumably due to three H-bonds and also hydrophobic interactions with the receptor molecule. The oxygen at the fifth position of oxazepine ring was H-bonded to Arg 750, hydrogen attached to nitrogen of indole ring to Asp 754 and hydrogen attached to N of the side chain to Val 748. High molecular weight (>500 Dalton) and high numbers of Hydrogen bond acceptors (>10) and donors (>5) may impair permeability across membrane bilayer. The Lipinski parameters for **2b** (mol. wt - 316, LogP - 1.2099, H-bond acceptors - 4 and H-bond donors - 3) suggests that it may have better oral bioavailability. Polar surface area of 128 Å² indicated the better oral absorption, intestinal permeability and passive transport of **2b**.

IV. CONCLUSION

Four new oxazepines were synthesized by the cycloaddition reaction between Schiff bases and maleic anhydride. 1-[2-(2,3-dihydro-1*H*-indol-3-yl)-4,7-dioxo-4,7-dihydro-1,3-oxazepin-3(2*H*)-yl]thiourea displayed cytotoxic and antimigratory properties. The docking studies revealed the compound as an excellent snail 1 inhibitor. Hence there is ample scope in taking up this oxazepine for further studies.

Experimental

1-[2-(4-hydroxyphenyl)-4,7-dioxo-4,7-dihydro-1,3-oxazepin-3(2*H*)-yl]thiourea(**2a**)

Yellow solid (80%) m.p.200-202 °C; IR (KBr) [cm⁻¹]: 3545 (OH str.), 3471, 3363 (NH₂ str.), 3193 (NH str.), 3050 (Ar. C-H str.), 1689 (C=O str.), 1550 (Ar. C=C str.), 1319 (C-O str.), 1234 (C=S str.); ¹H NMR DMSO d₆, 400MHz, 10.5 (1H, OH), 9.8 (1H, NH), 7.32-8.1 (4H, Ar. H), 7.24 (1H, O-CH-N), 6.34-7.01 (2H, CH=CH), 2.5(2H, NH₂); MS (m/z): 293 (M⁺).Anal.calcd. For C₁₂H₁₁N₃O₄S; C, 49.14; H, 3.75; N, 14.33. Found: C, 49.20; H, 3.76; N, 14.35.

1-[2-(2,3-dihydro-1*H*-indol-3-yl)-4,7-dioxo-4,7-dihydro-1,3-oxazepin-3(2*H*)-yl]thiourea(**2b**)

Brown solid (86%) m.p.270-274 °C; IR (KBr) [cm⁻¹]: 3448, 3317 (NH₂ str.), 3180 (NH str.), 3085 (Ar. C-H str.), 1689 (C=O str.), 1542 (Ar. C=C str.), 1315 (C-O str.), 1226 (C=S str.); ¹H NMR DMSO d₆, 400MHz, 10.1 (1H, indole NH), 9.8 (1H, NH), 7.33-8.2 (5H, Ar. H), 7.22 (1H, O-CH-N), 6.27-6.94 (2H, CH=CH), 2.5(2H, NH₂); MS (m/z): 316 (M⁺).Anal.calcd. For C₁₄H₁₂N₄O₃S; C, 53.16; H, 3.8; N, 17.72. Found: C, 53.23; H, 3.9; N, 17.76.

1-[2-(2,3-dimethoxyphenyl)-4,7-dioxo-4,7-dihydro-1,3-oxazepin-3(2*H*)-yl]thiourea(**2c**)

Yellow solid (80%) m.p.198-200 °C; IR (KBr) [cm⁻¹]: 3436, 3255 (NH₂ str.), 3155 (NH str.), 3047 (Ar. C-H str.), 2947 (CH₃ asym str.), 2831 (CH₃ sym str.), 1728 (C=O str.), 1535 (Ar. C=C str.), 1320 (C-O str.), 1272 (C=S str.); ¹H NMR DMSO d₆, 400MHz, 9.8 (1H, NH), 7.43-8.2(3H, Ar. H), 7.26 (1H, O-CH-N), 6.361-7.081 (2H, CH=CH), 3.89 (3H,

International Journal of Innovative Research in Science, Engineering and Technology

(An ISO 3297: 2007 Certified Organization)

Vol. 3, Issue 8, August 2014

OCH₃), 3.81 (3H, OCH₃), 2.5 (2H, NH₂); MS (m/z): 337 (M⁺); Anal. calcd. For C₁₄H₁₅N₃O₅S; C, 49.85; H, 4.45; N, 12.46. Found: C, 49.94; H, 4.47; N, 12.49.

1-[2-(4-hydroxy-3-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1,3-oxazepin-3(2H)-yl]thiourea(2d)

Yellow solid (85%) m.p.144 °C; IR (KBr) [cm⁻¹): 3523 (OH str.), 3433, 3278 (NH₂ str.), 3155 (NH str.), 3033 (Ar. C-H str.), 2939 (CH₃ asym str.), 2830 (CH₃ sym str.), 1720 (C=O str.), 1512 (Ar. C=C str.), 1320 (C-O str.), 1280 (C=S str.); ¹H NMR DMSO d₆, 400MHz, 10.8 (1H, OH), 9.78 (1H, NH), 7.39-8.1 (3H, Ar. H), 7.27 (1H, O-CH-N), 6.33-6.94 (2H, CH=CH), 3.88 (3H, OCH₃), 2.5 (2H, NH₂); MS (m/z): 323 (M⁺); Anal. calcd. For C₁₃H₁₃N₃O₅S; C, 48.29; H, 4.02; N, 13.00. Found: C, 48.35; H, 4.04; N, 13.04.

REFERENCES

- [1] Hanoon, H. D., "Synthesis and characterization of new seven-membered heterocyclic compounds from reaction of new schiff bases with maleic and phthalic anhydrides", National Journal of Chemistry, Vol.41, pp.77-89, 2011.
- [2] Hikmet, A., Berat, K., and Fatma, B., "Synthesis and structure-antibacterial activity relationship studies of 4-substituted phenyl-4,5-dihydrobenzo[f][1,4]oxazepin-3(2H)-thiones", Medicinal Chemistry Research, Vol.20, pp.1170-1180, 2011.
- [3] Serrano-Wu, M. H., Laurent, D. R., Chen, Y., Huang, S., Lam, K. R., Matson, J. A., Mazzucco, C. E., Stickle, T. M., Tully, T. P., Wong, H. S., Vyas, D. M., and Balasubramanian, B. N., "Sordarinoxazepine derivatives as potent antifungal agents", Bioorganic and Medicinal Chemistry Letters, Vol.12(19), pp.2757-2760, 2002.
- [4] Abdel-Hafez, A. A., and Abdel-Wahab, B. A., "5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation", Bioorganic and Medicinal Chemistry, Vol.16(17), pp.7983-7991, 2008.
- [5] Hallinan, E. A., Hagen, T. J., Tsymbalov, S., Husa, R. K., Lee, A. C., Stapelfeld, A., and Savage, M. A., "Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs", Journal of Medicinal Chemistry, Vol.39(2), pp.609-613, 1996.
- [6] Kubota, K., Kurebayashi, H., Miyachi, H., Tobe, M., Onishi, M., and Isobe, Y., "Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines", Bioorganic and Medicinal Chemistry, Vol.19(9), pp.3005-3021, 2011.
- [7] Xin-Hua, L., Ying-Ming, J., Bao-An, S., Zhi-xiang, P., and Song, Y., "Design and synthesis of novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives as telomerase inhibitors", Bioorganic and Medicinal Chemistry Letters, Vol.23(3), pp.720-723, 2013.
- [8] Kiran, B., Srivastava, V. K., and Ashok, K., "Synthesis of 1,5-benzothia/oxazepines as potent neuroleptic agents", Indian Journal of chemistry, Vol.42B, pp.1149-1155, 2003.
- [9] Halina, K., Malgorzata, S., and Agata, W., "Synthesis of aryl-fused 1,4-oxazepines and their oxo derivatives: A Review", Current Organic Synthesis, Vol.9(6), pp.828-850, 2012.
- [10] Roy, V. F., and Berx, G., "The cell-cell adhesion molecule E-cadherin", Cellular and Molecular Life Sciences, Vol.65(23), pp.3756-3788, 2008.
- [11] Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M., del Barrio, J. M. G., Portillo, F., and Nieto, M. A., "The transcription factor snail controls epithelial mesenchymal transitions by repressing E-cadherin expression", Nature Cell Biology, Vol.2(2), pp.76-83, 2000.
- [12] Polyak, K., and Weinberg, R. A., "Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits", Nature Review of Cancer, Vol.9(4), pp.265-273, 2009.
- [13] Thiery, J. P., Acloque, H., Huang, R. Y., and Nieto, M. A., "Epithelial-mesenchymal transitions in development and disease", Cell, Vol.139(50), pp.871-890, 2009.
- [14] Roussos, R. T., Keckesova, Z., Haley, J. D., Epstein, D. M., Weinberg, R. A., and Condeelis, J. S., "AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment", Cancer Research, Vol.70(19), pp.7360-7364, 2010.
- [15] Bezdekova, M., Brychtova, S., Sedlakova, E., Langova, K., Brychta, T., and Belej, K., "Analysis of snail-1, e-cadherin and claudin-1 expression in colorectal adenomas and carcinomas", International Journal of Molecular Sciences, Vol.13(2), pp.1632-1643, 2012.
- [16] Stemmer, V., de Craene, B., Berx, G., and Behrens, J., "Snail promotes Wnt target gene expression and interacts with beta-catenin", Oncogene, Vol.27(37), pp.5075-5080, 2008.
- [17] Larriba, M. J., Valle, N., Palmer, H. G., Ordonez-Moran, P., Alvarez-Diaz, S., Becker, K. F., Gamallo, C., de Herreros, A. G., Gonzalez-Sancho, J. M., and Munoz, A., "The inhibition of Wnt/beta-catenin signaling by Ialpha, 25-dihydroxyvitamin D3 is abrogated by snail1 in human colon cancer cells", Endocrine Related Cancer, Vol.14(1), pp.141-151, 2007.
- [18] Yokoyama, K., Kamata, N., Hayashi, E., Hoteiya, T., Ueda, N., Fujimoto, R., and Nagayama, M., "Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro", Oral Oncology, Vol.37(1), pp.65-71, 2001.
- [19] Jiao, W., Miyazaki, K., and Kitajima, Y., "Inverse correlation between E-cadherin and snail expression in hepatocellular carcinoma cells invitro and in vivo", British Journal of cancer, Vol.86(1), pp.98-101, 2002.
- [20] Katoh, M., "Epithelial-mesenchymal transition in gastric cancer", International Journal of Oncology, Vol.27(6), pp.1677-1683, 2005.
- [21] Peinado, H., Olmeda, D., and Cano, A., "Snail, Zeb nab HLH factors in tumor progression:an alliance against the epithelial phenotype?", Nature Review of Cancer, Vol.7(6), pp.415-428, 2007.
- [22] Olmeda, D., Jorda, M., Peinado, H., Fabra, A., and Cano A., "Snail silencing effectively suppresses tumor growth and invasiveness", Oncogene, Vol.26(13), pp.1862-1874, 2007.
- [23] Loboda, A., Nebozhyn, M. V., Watters, J. W., Buser, C. A., Shaw, P. M., Huang, P. S., Van't Veer, L., Tollenaar, R. A., Jackson, D. B., and Agrawal, D., "EMT is the dominant program in human colon cancer", BMC Medical Genomics, Vol.4, pp.9, 2011.
- [24] Yusra, S., and Yokozaki, H., "Biological significance of tumor budding at the invasive front of human colorectal carcinoma cells", International Journal of Oncology, Vol.41(1), pp.201-210, 2012.

International Journal of Innovative Research in Science, Engineering and Technology

(An ISO 3297: 2007 Certified Organization)

Vol. 3, Issue 8, August 2014

- [25] Feride, K., Georg, F., Daniel, V., Stephan, E. B., Levent, D., Andreas, M. R., Dieter, H., Nikolas, H. S., and Wolfram, T. K., "Snail1 expression in colorectal cancer and its correlation with clinical and pathological parameters", BMC Cancer, Vol.13, pp.145-153, 2013.
- [26] Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R., "New colorimetric cytotoxicity assay for anticancer-drug screening", Journal of The National Cancer Institute, Vol.82(13), pp.1107-1112, 1990.
- [27] Hostanska, K., Nisslein, T., Freudenstein, J., Reichling, J., and Saller, R., "Inhibitory effect of an isopropanolic extract of black cohosh on the invasiveness of MDA-MB 231 human breast cancer cells", In Vivo, Vol.2, pp.1349-356, 2007.
- [28] Lipinski, C. A., "Drug-like properties and the cause of poor solubility and poor permeability", Journal of Pharmacological and Toxicological Methods, Vol.44, pp.235-249, 2008.
- [29] Vaid, M., Singh, T., and Katiyar, S. K., "Grape seed proanthocyanidins inhibit melanoma cell invasiveness by reduction of PGE2 synthesis and reversal of epithelial-to-mesenchymal transition", PLOS One, Vol.6, e21539, 2011.

IJIRSET